Pain Therapeutics (NASDAQ:PTIE) – Stock analysts at Gabelli raised their FY2017 earnings per share (EPS) estimates for Pain Therapeutics in a research note issued on Monday. Gabelli analyst K. Kedra now expects that the biopharmaceutical company will earn ($2.35) per share for the year, up from their prior forecast of ($2.80). Gabelli has a “Sell” rating on the stock. Gabelli also issued estimates for Pain Therapeutics’ FY2018 earnings at ($2.90) EPS, FY2019 earnings at ($4.85) EPS, FY2020 earnings at ($4.50) EPS and FY2021 earnings at ($3.35) EPS.

Several other analysts have also recently weighed in on PTIE. Zacks Investment Research cut Pain Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, July 14th. ValuEngine cut Pain Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at

Shares of Pain Therapeutics (NASDAQ PTIE) traded down 0.954% during mid-day trading on Wednesday, reaching $3.635. The company’s stock had a trading volume of 5,444 shares. The firm’s market cap is $23.96 million. The firm has a 50 day moving average price of $3.95 and a 200 day moving average price of $1.88. Pain Therapeutics has a 52-week low of $3.39 and a 52-week high of $21.00.

Pain Therapeutics (NASDAQ:PTIE) last issued its earnings results on Tuesday, April 25th. The biopharmaceutical company reported ($0.42) EPS for the quarter, meeting analysts’ consensus estimates of ($0.42).

An institutional investor recently raised its position in Pain Therapeutics stock. Bank of New York Mellon Corp increased its stake in shares of Pain Therapeutics (NASDAQ:PTIE) by 10.8% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 172,792 shares of the biopharmaceutical company’s stock after buying an additional 16,864 shares during the period. Bank of New York Mellon Corp owned about 0.38% of Pain Therapeutics worth $154,000 as of its most recent filing with the SEC.

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.